New York, USA – September 29, 2026 – The 22q11.2 Deletion Syndrome market is poised for significant evolution, driven by advancements in genetic testing and diagnosis, increasing awareness of rare genetic disorders, growing research and development activities, supportive regulatory initiatives, and the need for multidisciplinary management of this complex chromosomal disorder. The therapeutic landscape remains largely supportive, with no broadly available disease-modifying therapy for the multisystem manifestations of 22q11.2 Deletion Syndrome. However, emerging candidates such as NB-001 are being investigated to address neuropsychiatric manifestations and potentially expand disease-specific treatment options.
According to DelveInsight, the 22q11.2 Deletion Syndrome market was valued at approximately USD 14 million in 2025 and is projected to grow at a CAGR of approximately 32% during 2026–2036. The market analysis covers the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
DelveInsight’s report, “22q11.2 Deletion Syndrome Market Insights, Epidemiology and Market Forecast – 2036,” provides comprehensive insights into disease epidemiology, patient burden, current treatment practices, emerging therapies, competitive landscape, market size, unmet needs, and future market opportunities across the seven major markets.
Key Takeaways
Keen to know more about the 22q11.2 Deletion Syndrome market? Request our sample page at: https://www.delveinsight.com/sample-request/22q112-deletion-syndrome-market
Key Factors Driving the 22q11.2 Deletion Syndrome Market
Advancements in Genetic Testing and Diagnosis
Improved molecular diagnostic technologies are supporting earlier and more accurate identification of 22q11.2 Deletion Syndrome. Chromosomal microarray is described by DelveInsight as the current gold standard for genetic confirmation, while increasing use of genomic-first approaches and prenatal screening is contributing to improved detection.
Increasing Awareness of Rare Genetic Disorders
Growing awareness among healthcare professionals, caregivers, and patient advocacy organizations is supporting recognition of the heterogeneous clinical presentation of 22q11.2 Deletion Syndrome. Greater disease awareness can contribute to improved diagnosis and identification of patients requiring multidisciplinary care.
Growing Research and Development Activities
Pharmaceutical and biotechnology companies are investigating targeted approaches for the disease and its associated neuropsychiatric and immune manifestations. The emergence of mechanism-based therapies such as NB-001 represents a shift beyond purely symptomatic treatment.
Supportive Government and Regulatory Initiatives
Orphan-drug incentives, rare-disease research funding, and regulatory programs designed to facilitate development of therapies for serious pediatric conditions can support investment in the 22q11.2 Deletion Syndrome therapeutic landscape. NB-001 has received FDA Rare Pediatric Disease designation, while Nobias Therapeutics has secured preliminary FDA alignment regarding registrational endpoints.
Growing Demand for Multidisciplinary Care
The multisystem nature of 22q11.2 Deletion Syndrome requires coordination among cardiology, immunology, endocrinology, developmental medicine, neurology, and psychiatry. Increasing recognition of these long-term care requirements contributes to healthcare resource utilization and creates demand for more integrated management strategies.
Competitive Landscape
The 22q11.2 Deletion Syndrome competitive landscape consists of companies developing regenerative, small-molecule, and symptom-focused therapeutic approaches.
Key companies include:
The principal therapies highlighted by DelveInsight include RETHYMIC and the investigational NB-001, while Zygel (ZYN002) represents a previously investigated approach for behavioral symptoms whose development in 22q11.2 Deletion Syndrome has been paused.
Discover more about therapies set to impact the 22q11.2 Deletion Syndrome market @ DelveInsight – 22q11.2 Deletion Syndrome Market Insights
Recent Developments in the 22q11.2 Deletion Syndrome Market
What is 22q11.2 Deletion Syndrome?
22q11.2 Deletion Syndrome (22q11.2DS) is a chromosomal microdeletion disorder caused by deletion of genetic material at chromosome 22q11.2. It is also known as DiGeorge syndrome or velocardiofacial syndrome.
The condition results from haploinsufficiency of several genes, including TBX1, and can affect multiple organ systems. Common manifestations include congenital heart defects, thymic hypoplasia and immune dysfunction, hypoparathyroidism-associated hypocalcemia, craniofacial abnormalities, developmental difficulties, learning disabilities, autism spectrum disorder, and psychiatric manifestations.
DelveInsight estimates the prevalence at approximately 1 in 3,000–4,000 live births, making 22q11.2 Deletion Syndrome the most common chromosomal microdeletion syndrome. The clinical presentation is highly variable, which contributes to underdiagnosis and delayed diagnosis, particularly among individuals without major congenital abnormalities.
Diagnosis is generally confirmed through genetic testing, with chromosomal microarray (CMA) serving as the current gold-standard diagnostic approach described in the report.
22q11.2 Deletion Syndrome Epidemiology Segmentation
The DelveInsight epidemiology assessment evaluates the 22q11.2 Deletion Syndrome patient population across several clinically relevant categories:
According to DelveInsight’s estimates, approximately 101,500 diagnosed prevalent cases of 22q11.2 Deletion Syndrome were present across the 7MM in 2025.
In the United States, the age-specific diagnosed prevalent population in 2025 included approximately 12,550 infants, 10,300 patients aged 1–5 years, 19,550 patients aged 6–12 years, 4,800 patients aged 13–17 years, and 7,000 adults.
Among the EU4 and UK, Germany recorded approximately 9,300 diagnosed prevalent cases, representing the highest burden among those markets, while Spain had approximately 6,100 cases in 2025. Japan had approximately 7,650 diagnosed prevalent cases with behavioral and psychiatric phenotypes.
Current Treatment Landscape
There is currently no curative treatment addressing the underlying genetic defect across the broad spectrum of 22q11.2 Deletion Syndrome. Management remains supportive, symptom-driven, and multidisciplinary, with treatment tailored according to age, disease severity, and organ involvement.
Management of Congenital Heart Defects
Patients with significant congenital heart abnormalities may require surgical correction or other cardiovascular interventions. Cardiac management is particularly important during infancy and early childhood.
Management of Immune Dysfunction
Immune abnormalities may require infection prevention, antimicrobial management, immunoglobulin replacement in selected patients, and specialized immunological monitoring. For severe T-cell deficiency associated with congenital athymia, thymus transplantation may be considered.
Management of Hypocalcemia
Hypoparathyroidism and hypocalcemia are managed through calcium and vitamin D supplementation and appropriate endocrine monitoring.
Developmental and Psychiatric Management
Speech, occupational, behavioral, and developmental interventions are used to address neurodevelopmental difficulties. Psychiatric management may include treatment of ADHD, anxiety, and schizophrenia when these conditions occur.
Approved Therapy
RETHYMIC – Sumitomo Pharma/Enzyvant/Roivant Sciences
RETHYMIC (formerly RVT-802) is a thymus tissue-based regenerative therapy indicated for patients with congenital athymia, a rare and life-threatening immune deficiency that can occur in association with 22q11.2 Deletion Syndrome.
The therapy involves implantation of allogeneic cultured thymus tissue to restore T-cell development and immune function. According to the DelveInsight report, RETHYMIC was approved in 2021 and represents a disease-modifying treatment option for the severe immune-deficiency component of this patient population.
Emerging Therapy
NB-001 (Fasoracetam) – Nobias Therapeutics
NB-001, also referred to as fasoracetam, is an investigational non-stimulant activator of multiple metabotropic glutamate receptors (mGluRs). It is being developed to target disrupted glutamatergic signaling associated with cognitive and psychiatric manifestations of 22q11.2 Deletion Syndrome.
The therapy has completed a Phase II clinical trial and has received FDA Rare Pediatric Disease designation. In June 2025, Nobias Therapeutics reported preliminary alignment with the FDA regarding registrational endpoints, providing greater clarity for the potential development pathway of NB-001.
Zygel (ZYN002) – Development Status
Zygel (ZYN002), a transdermal cannabidiol gel developed by Zynerba Pharmaceuticals, was investigated for behavioral symptoms associated with 22q11.2 Deletion Syndrome.
The report notes that the development program was paused pending a full review of RECONNECT data. This leaves the asset as a previously investigated approach rather than an actively progressing disease-specific program in the current landscape described by DelveInsight.
Unmet Needs in 22q11.2 Deletion Syndrome
Despite advances in diagnosis and supportive care, substantial unmet needs remain across the 22q11.2 Deletion Syndrome treatment landscape.
Key unmet needs include:
The heterogeneous presentation of 22q11.2 Deletion Syndrome further complicates the development of standardized treatment pathways and contributes to variation in diagnosis and disease management.
Scope of the 22q11.2 Deletion Syndrome Market Report
The 22q11.2 Deletion Syndrome Market Report – 2036 provides a comprehensive assessment of the disease and therapeutic landscape, including:
The report covers the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan, with the historical period covering 2022–2025 and the forecast period spanning 2026–2036.
To know more about 22q11.2 Deletion Syndrome companies and emerging therapies, request a sample copy of the report: Request Sample Report
Table of Contents
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through its subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kirti SharmaEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services
